Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig vs Durvalumab in Unresectable Stage III NSCLC
NCT07361497Phase 3
Key facts
- Status
- Recruiting
- Start
- Mar 2026
- Primary completion
- Sep 2030
- Countries
- 32
- Sponsor
- Bristol Myers Squibb
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Drugs
- pumitamig
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 3, randomised, open-label trial of pumitamig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-Free Survival at 3 years. Started Mar 2026; status: recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Arm A
Experimental: Pumitamig
Arm B
Active Comparator: Durvalumab
03
Who it enrols
Participants must have unresectable Stage III NSCLC without progression after at least 2 cycles of platinum-based concurrent chemoradiotherapy, ECOG PS 0-1, and no EGFR/ALK rearrangements if non-squamous.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Progression-Free Survival
Objective Response
Disease Control Rate
Duration of Response
Time to Response
Beyond the preview
Go deeper on NCT07361497.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361497.